

# Devendra K Hiwase

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5585985/devendra-k-hiwase-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57  
papers

616  
citations

12  
h-index

24  
g-index

64  
ext. papers

830  
ext. citations

3.6  
avg, IF

3.43  
L-index

#	Paper	IF	Citations
57	Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3881-8	12.9	157
56	Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 116-24	4.7	66
55	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. <i>Blood</i> , <b>2015</b> , 125, 915-23	2.2	65
54	Myeloid neoplasms with germline DDX41 mutation. <i>International Journal of Hematology</i> , <b>2017</b> , 106, 163-174	3.4	44
53	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. <i>Blood Advances</i> , <b>2020</b> , 4, 1131-1144	7.8	37
52	Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. <i>Haematologica</i> , <b>2017</b> , 102, 2021-2029	6.6	28
51	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. <i>Leukemia</i> , <b>2019</b> , 33, 2842-2853	10.7	19
50	Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 508-514	7.1	16
49	Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 114-120	3.6	16
48	Inflammatory myopathies after allogeneic stem cell transplantation. <i>Muscle and Nerve</i> , <b>2018</b> , 58, 790-795	3.4	15
47	Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. <i>Blood</i> , <b>2019</b> , 134, 85-89	2.2	14
46	Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. <i>Blood</i> , <b>2013</b> , 122, 1503-1503	2.2	13
45	Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. <i>Haematologica</i> , <b>2013</b> , 98, 896-900	6.6	11
44	Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. <i>HemaSphere</i> , <b>2019</b> , 3, e314	0.3	11
43	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , <b>2020</b> , 105, e98-e101	6.6	10
42	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. <i>Leukemia</i> , <b>2021</b> , 35, 3245-3256	10.7	10
41	Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. <i>Leukemia Research</i> , <b>2018</b> , 67, 109-115	2.7	8

40	Clinical Effectiveness of Conjugate Pneumococcal Vaccination in Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 421-427	4.7	7
39	Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 152-159	1.6	7
38	Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance. <i>Haematologica</i> , <b>2019</b> , 104, e451-e454	6.6	6
37	Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 782-788	4.7	6
36	Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. <i>Expert Review of Hematology</i> , <b>2011</b> , 4, 285-99	2.8	5
35	Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 700-709	6.6	5
34	Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study. <i>HemaSphere</i> , <b>2019</b> , 3, e224	0.3	4
33	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 2011-2011	2.2	3
32	The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. <i>Transfusion</i> , <b>2020</b> , 60, 2192-2198	2.9	3
31	Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. <i>Blood Advances</i> , <b>2019</b> , 3, 370-374	7.8	2
30	Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1251-2	1.9	2
29	Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. <i>Blood</i> , <b>2018</b> , 132, 3101-3101	2.2	2
28	Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients. <i>Blood</i> , <b>2013</b> , 122, 1518-1518	2.2	2
27	Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations. <i>Blood</i> , <b>2016</b> , 128, 1212-1212	2.2	2
26	A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML. <i>HemaSphere</i> , <b>2018</b> , 2, e158	0.3	2
25	Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 128-130	3.6	2
24	Correct application of variant classification guidelines in germline mutated disorders to assist clinical diagnosis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 246-247	1.9	2
23	Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 133	22.4	2

22	Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. <i>Blood Advances</i> , <b>2021</b> , 5, 5107-5111	7.8	2
21	Success is built on failures: tackling the challenge of ponatinib failure. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1279-1281	1.9	1
20	Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	1
19	Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. <i>Blood</i> , <b>2015</b> , 126, 1644-1644	2.2	1
18	Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7056-7056	2.2	1
17	Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups. <i>Blood</i> , <b>2021</b> , 138, 3702-3702	2.2	1
16	Outcomes and health care utilization of older patients with acute myeloid leukemia. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 243-249	3.6	1
15	A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia. <i>Blood</i> , <b>2021</b> , 138, 1261-1261	2.2	0
14	A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes. <i>Blood</i> , <b>2021</b> , 138, 3675-3675	2.2	0
13	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. <i>Blood</i> , <b>2021</b> , 138, 368-368	2.2	0
12	Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS. <i>Blood</i> , <b>2021</b> , 138, 1532-1532	2.2	0
11	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. <i>Blood</i> , <b>2021</b> , 138, 2351-2351	2.2	0
10	Childhood acute myeloid leukemia shows a high level of germline predisposition. <i>Blood</i> , <b>2021</b> , 138, 2293-2298	2.2	0
9	The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. <i>Leukemia Research</i> , <b>2017</b> , 57, 102-103	2.7	
8	Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes. <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	
7	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. <i>Blood</i> , <b>2021</b> , 138, 3377-3377	2.2	
6	Prevalence of Cardiac and Hepatic Siderosis in Australian Patients with Transfusion-Dependent Anemias or Non-Transfusion-Dependent Thalassemia, As Assessed By MRI (the TIMES study). <i>Blood</i> , <b>2015</b> , 126, 540-540	2.2	
5	RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. <i>Blood</i> , <b>2015</b> , 126, 3562-3562	2.2	

- 4 Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study. *Blood*, **2016**, 128, 5447-5447 2.2
- 3 High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?. *Blood*, **2016**, 128, 3989-3989 2.2
- 2 Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia 281-295
- 1 STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner. *Blood*, **2013**, 122, 2705-2705 2.2